Wells Fargo & Company MN Sells 37,874 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Wells Fargo & Company MN lessened its stake in AtriCure, Inc. (NASDAQ:ATRC) by 39.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,407 shares of the medical device company’s stock after selling 37,874 shares during the quarter. Wells Fargo & Company MN owned approximately 0.12% of AtriCure worth $1,754,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Heck Capital Advisors LLC purchased a new stake in shares of AtriCure in the fourth quarter valued at about $60,000. Venturi Wealth Management LLC grew its position in AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after purchasing an additional 2,100 shares in the last quarter. KBC Group NV increased its stake in AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after buying an additional 932 shares during the last quarter. R Squared Ltd bought a new position in shares of AtriCure during the 4th quarter worth approximately $89,000. Finally, AlphaQuest LLC boosted its stake in shares of AtriCure by 855.1% in the 4th quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company’s stock worth $155,000 after buying an additional 4,532 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ATRC. Needham & Company LLC reaffirmed a “buy” rating and set a $51.00 price target on shares of AtriCure in a research report on Thursday, March 27th. BTIG Research reaffirmed a “buy” rating on shares of AtriCure in a research report on Thursday, March 27th. Canaccord Genuity Group cut their price target on shares of AtriCure from $66.00 to $52.00 and set a “buy” rating on the stock in a report on Friday, March 28th. JMP Securities restated a “market outperform” rating and set a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. Finally, Oppenheimer lifted their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.44.

AtriCure Trading Down 1.0 %

Shares of ATRC opened at $33.40 on Friday. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.65 billion, a PE ratio of -35.16 and a beta of 1.65. The business’s 50-day moving average price is $34.32 and its 200-day moving average price is $34.60.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.50% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.